Editorial
Copyright ©2010 Baishideng Publishing Group Co.
World J Hepatol. Sep 27, 2010; 2(9): 325-336
Published online Sep 27, 2010. doi: 10.4254/wjh.v2.i9.325
Figure 1
Figure 1 Time to the onset of cytomegalovirus disease in solid organ transplant recipients who received three mo of oral ganciclovir or valganciclovir prophylaxis. Data obtained from the study by Paya and colleagues[5].
Figure 2
Figure 2 Suggested algorithm for preemptive therapy. Figure adapted from reference [62].
Figure 3
Figure 3 Proportion of solid organ transplant patients with resolution of clinical symptoms (panel A) and viremia eradication (panel B) at day 21 and 49 following the start of valganciclovir or intravenous ganciclovir treatment of CMV disease. Data obtained from the study by Asberg and colleagues[79].